Year Wrapped: Tryptamine Therapeutics 2024 Milestones, Clinical Breakthroughs & 2025 Vision | ASX:TYP, OTC:TYPTF

Proactive InvestorsDec 19 18:25 ET

Tryptamine Therapeutics Fields Positive Early Results in Phase 2a Irritable Bowel Syndrome Trial

Investing.com Dec 17 18:56 ET

Tryptamine Therapeutics Phase 1b Study Refines Dose of IV Psilocin in Obese Subjects

Investing.com Dec 15 19:45 ET

Tryptamine Therapeutics Issues 47 Million Unquoted Options

TipRanksDec 2 00:47 ET

Tryptamine Therapeutics Completes Dosing of First Subject in Obesity Study

MT NewswiresNov 21 21:39 ET

Tryptamine Therapeutics Doses First Patient in IV-infused Psilocin Phase 1b Study

Investing.com Nov 21 18:10 ET